Хроническая сердечная недостаточность и сахарный диабет: патогенез и возможности лечения
Аннотация
Ключевые слова
сердечная недостаточность,
сахарный диабет,
патогенез,
лечение,
heart failure,
diabetes mellitus,
pathogenesis,
treatment
Об авторах
А. Г. Обрезан
ФГБОУ ВО «Санкт-Петербургский государственный университет»; ООО «Международный медицинский центр «СОГАЗ»
Россия
Россия
Н. В. Куликов
ФГБОУ ВО «Санкт-Петербургский государственный университет»
Россия
Россия
Список литературы
1. Акимов А. Г., Обрезан А. Г. Лечение хронической сердечной недостаточности: современные российские и международные рекомендации. Санкт-Петербург, 2010, 360 c.
2. Мамедов М. Н., Марданов Б. У., Дудинская Е. Н. Сердечная недостаточность у больных сахарным диабетом: диагностика, лечение, профилактика. М.: Фонд «Кардиопрогресс»; 2015, 106 с.
3. Обрезан А. Г., Бицадзе Р. М. Структура сердечно-сосудистых заболеваний у больных сахарным диабетом 2-го типа, диабетическая кардиомиопатия как особое состояние миокарда. Вестник Санкт-Петербургского университета. Медицина 2008;2:47-53
4. Kannel W. B., Hjortland M., Castelli W. P. Role of diabetes in congestive heart failure: the Framingham study. Am J. Cardiol 1974;34 (1):29-34. PMID: 4835750
5. Thrainsdottir I. S., Aspelund T., Thorgeirsson G. et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005;28:612-616; PMID: 15735197.
6. Smaradottir M. I., Ritsinger V., Gyberg V. et al. Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker ofincreased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diab Vasc Dis Res 2017;14 (2):69-76. DOI: 10.1177/1479164116664490.
7. Lee A. K., Warren B., Lee C. J. et al. The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes. Diabetes Care 2018;41 (1):104-111 DOI: 10.2337/dc17-1669.
8. Бицадзе Р. М., Дорофейков В. В., Обрезан А. Г. Метаболические особенности сердечно-сосудистой патологии у больных сахарным диабетом 2-го типа Вестник Санкт-Петербургского университета. Медицина 2009;1:3-10
9. Косарев М. М., Обрезан А. Г., Стрельников А. А., Гурьянова А. В. Современные принципы диагностики хронической сердечной недостаточности. Клиническая медицина 2011;89 (4):8-13
10. Duprez D. A., Gross M. D., Kizer J. R. et al. Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am Heart Assoc 2018;7 (5). pii: e007885. DOI: 10.1161/JAHA. 117.007885.
11. World Health Organization. Global report on diabetes. WHO Library Cataloguing-in-Publication Data. 2016 ISBN 9789241565257 (NLM classification: WK 810).
12. Общая заболеваемость взрослого населения России в 2016 году. Статистические материалы. Часть IV. Москва. 2017, 160 стр.) http://mednet.ru/.
13. Медико-демографические показатели Российской Федерации в 2016 году. Стат. справочник/Минздрав России. М., 2017; 254 c. http://mednet.ru/
14. Matsue Y., Suzuki M., Nakamura Abe M. et al. Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J. 2011;75:2833-2839. PMID: 22008319
15. Lawson C. A., Jones P. W., Teece L. et al. Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification. JACC Heart Fail 2018;6 (1):18-26. DOI: 10.1016/j.jchf. 2017.08.020.
16. Sokoreli I., Pauws S. C., Steyerberg E. W. et al. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPE^A-HF study. EurJ Heart Fail 2018;20 (4):689-696. DOI: 10.1002/ejhf. 1112.
17. Cunha F. M., Pereira J., Ribeiro A. et al. Age affects the prognostic impact of diabetes in chronic heart failure. Acta Diabetol 2018;55 (3):271-278. DOI: 10.1007/s00592-017-1092-9.
18. Bjorck L. M., Lanitis M., Lappas G. et al. Mortality Trends 1987 to 2004 in 404,480 Hospitalized Heart Failure Patients with and without Diabetes. Circulation 2012;125: AP208 (Abstract) http:// circ.ahaj ournals.org / content /125/ Suppl_10 / AP208.
19. MacDonald M. R., Petrie M. C., Varyani F. et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377-138 DOI: 10.1093/eurheartj/ehn153.
20. Levelt E., Mahmod M., Piechnik S. K. et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes 2016;65:44-52 DOI: 10.2337/db15-0627.
21. Levelt E., Pavlides M., Banerjee R. et al. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J. Am Coll Cardiol 2016;68:53-63. DOI: 10.1016/j.jacc. 2016.03.597.
22. Shimizu I., Minamino T., Toko H. et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin Invest 2010;120 (5):1506-1514. DOI: 10.1172/JCI40096.
23. Levelt E., Rodgers C. T., Clarke W. T. et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J. 2016;37:3461-3469 DOI: 10.1093/eurheartj/ehv442.
24. Falcao-Pires I., Hamdani N., Borbély A. et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011;124:1151-1159. DOI: 10.1161/ CIRCUL ATIONAHA. 111.025 270.
25. Bonapace S., Valbusa F., Bertolini L. et al. Early impairment in left ventricular longitudinal systolic function is associated with an increased risk of incident atrial fibrillation in patients with type 2 diabetes. J. Diabetes Complications 2017;31:413-418. DOI: 10.1016/j.jdiacomp. 2016.10.032.
26. Montaigne D., Marechal X., Coisne A. et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 2014;130 (7):554-564. DOI: 10.1161 / CIRCULATIONAHA. 113.008476.
27. Glass C. K., Olefsky J. M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012;15:635-645. DOI: 10.1016/j.cmet. 2012.04.001.
28. Rijzewijk L.J., Jonker J. T., van der Meer R. W. et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J. Am Coll Cardiol 2010;56:225-233. DOI: 10.1016/ j.jacc. 2010.02.049.
29. Liesa M., Shirihai O. S. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab 2013;17 (4):491-506. DOI: 10.1016/j.cmet. 2013.03.002.
30. Shah M. S., Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res 2016;118:1808-1829. DOI: 10.1161/ CIRCRES AHA. 116.306923.
31. Bedi K. C. Jr., Snyder N. W., Brandimarto J. et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 2016;133:706-716. DOI: 10.1161/ CIRCULATIONAHA. 115.017545.
32. Aubert G., Martin O.J., Horton J. L. et al. The failing heart relies on ketone bodies as a fuel. Circulation 2016;133:698-705. DOI: 10.1161/CIRCULATIONAHA. 115.017355.
33. Campbell P., Krim S., Ventura H. The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes - A review of the Epidemiology and Outcomes. Card Fail Rev 2015; (1):8-10. DOI: 10.15420/cfr. 2015.01.01.8.
34. Look AHEAD Research Group, Wing R. R., Bolin P., Brancati F. L. et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-154. DOI: 10.1056/NEJMoa1212914.
35. Look AHEAD Research Group, Gregg E. W.,Jakicic J. M., Blackburn G. et al. Association ofthe magnitude ofweight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913-921. DOI: 10.1016/S2213-8587 (16) 30162-0.
36. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M. et al. Effect ofintensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343: d4169. DOI: 10.1136/bmj. d4169.
37. Lehrke М., Marx N. Diabetes Mellitus and Heart Failure. AJMPlus 2017;130 (6):S40 - S50. DOI: 10.1016/j.amjmed. 2017.04.010.
38. Pryor R., Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471:307-322. DOI: 10.1042/BJ20150497.
39. Sharma D. C., Asirvatham A., Singh P. Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure Indian J. Endocrinol Metab 2017; 21 (4):618-629. DOI: 10.4103/ijem. IJEM_442_16.
40. Aguilar D., Chan W., Bozkurt B. et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011;4:53-58. DOI: 10.1161/ CIRCHEARTFAILURE. 110.952556.
41. Crowley M.J., Diamantidis C.J., McDuffie J. R. et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 2017;166:191-200. DOI: 10.7326/M16-1901.
42. Boussageon R., Supper I., Bejan-Angoulvant T. et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a metaanalysis of randomised controlled trials. PLoS Med 2012;9: e1001204. DOI: 10.1371/journal. pmed. 1001204.
43. Ou S. M., Shih C.J., Chao P. W. et al. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med 2015;163 (9):663-672. DOI: 10.7326/M15-0308.
44. Fadini G. P., Avogaro A., Esposti L. D. et al. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J. 2015;36:2454-2462. DOI: 10.1093/eurheartj/ehv301.
45. BARI 2D Study Group, Frye R. L., August P., Brooks M. M. et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl J. Med 2009;360:2503-2515. DOI: 10.1056/NEJMoa0805796.
46. Nassif M., Kosiborod M. Effect of glucose-lowering therapies on heart failure. Nat Rev Cardiol 2018;15 (5):282-291. DOI: 10.1038/nrcardio. 2017.211.
47. Smooke S., Horwich T. B., Fonarow G. C. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149 (1):168-174. DOI: 10.1016/j.ahj. 2004.07.005.
48. Gamble J. M., Chibrikov E., Twells L. K. et al. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol 2017;5:43-45. DOI: 10.1016/S2213-8587 (16) 30316-3.
49. Hernandez A. V., Usmani A., Rajamanickam A., Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk oftype 2 diabetes mellitus: a meta-analysis and meta-regression analysis ofplacebo-controlled randomized clinical trials. AmJ Cardiovasc Drugs 2011;11:115-128. DOI: 10.2165/ 11587580-000000000-00000.
50. Scirica B. M., Bhatt D. L., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl J. Med 2013;369:1317-1326. DOI: 10.1056/NEJMoa1307684.
51. White W. B., Cannon C. P., Heller S. R. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl J. Med 2013;369:1327-1335. DOI: 10.1056/NEJMoa1305889.
52. Green J. B., Bethel M. A., Armstrong P. W. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl J. Med 2015;373:232-242. DOI: 10.1056/NEJMoa1501352.
53. Spinar J., Spinarova L., Vitovec J. The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes? Vnitr Lek 2015;61 (11):976-983. PMID: 26652787.
54. Bergmark B. A., Scirica B. M., Steg P. G. et al. SAVOR-TIMI 53 Investigators. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. Eur Heart J. 2018; Jan 31. DOI: 10.1093/eurheartj/ehx809.
55. Sato A., Yoshihisa A., Kanno Y. et al. Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus. ESC Heart Fail 2016;3:77-85. DOI: 10.1002/ehf2.12079.
56. Toh S., Hampp C., Reichman M. E. et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med 2016;164:705-714. DOI: 10.7326/M15-2568.
57. Meier J. J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-742. DOI: 10.1038/nrendo. 2012.140.
58. Lupsa B. C., Inzucchi S. E. Diabetes medications and cardiovascular disease: at long last progress. Curr Opin Endocrinol Diabetes Obes 2018;25 (2):87-93. DOI: 10.1097/MED. 0000000000000400.
59. Pfeffer M. A., Claggett B., Diaz R. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl J. Med 2015;373:2247-2257. DOI: 10.1056/NEJMoa1509225.
60. Guthrie R. Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes. Postgrad Med 2018; Jan 25:1-5. DOI: 10. 1080/00325481.2018.1430446.
61. Margulies K. B., Hernandez A. F., Redfield M. M. et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500-508. DOI: 10.1001/jama. 2016.10260.
62. Lepore J.J., Olson E., Demopoulos L. et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail 2016;4:559-566. DOI: 10.1016/j.jchf. 2016.01.008.
63. Zinman B., Wanner C., Lachin J. M. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl J. Med 2015;373:2117-2128. DOI: 10.1056/NEJMoa1504720.
64. Wanner C., Lachin J. M., Inzucchi S. E. et al. EMPA-REG OUTCOME Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation 2018;137 (2):119-129. DOI: 10.1161 /circulationaha. 117.028268.
65. Ferrannini E., Mark M., Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate" hypothesis. Diabetes Care 2016;39:1108-1114. DOI: 10.2337/dci16-0033.
66. Low Wang C., Hess C. N., Hiatt W. R., Goldfine A. B. Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes -Mechanisms, Management, and Clinical Considerations. Circulation 2016;133 (24):2459-2502. DOI: 10.1161/circulationaha. 116.022194.
67. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 8-й выпуск, М.: УП ПРИНТ; 2017; 112 c.). DOI: 10.14341 /DM20171S8.
68. Doggrell S. A. Cardiovascular outcomes with canagliflozin - is it on the CANVAS? Expert Opin Pharmacother 2018;19 (2):163-166. DOI: 10.1080/14656566.2017. 1418855.
69. Neal B., Perkovic V., Mahaffey K. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New Engl J. Med 2017;377 (7):644-657. DOI: 10.1056/NEJMoa1611925.
Рецензия
Для цитирования:
Обрезан А.Г., Куликов Н.В. Хроническая сердечная недостаточность и сахарный диабет: патогенез и возможности лечения. Кардиология. 2018;58(7):85-94. https://doi.org/10.18087/cardio.2018.7.10156
For citation:
Obrezan A.G., Kulikov N.V. Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment. Kardiologiia. 2018;58(7):85-94. (In Russ.) https://doi.org/10.18087/cardio.2018.7.10156
Просмотров: 2702
Послать статью по эл. почте 
Оставить комментарий 